Understanding clopidogrel resistance: Mechanisms, detections, implications and surmount the clopidogrel resistant in order to potential solutions
Department Of Pharmacy Practice, A. M. Reddy Memorial College of Pharmacy, Acharya Nagarjuna University, Narasaraopet, India.
Review Article
World Journal of Advanced Research and Reviews, 2023, 19(02), 907–921
Publication history:
Received on 14 June 2023; revised on 18 August 2023; accepted on 20 August 2023
Abstract:
Clopidogrel, a drug belonging to the thienopyridine class of antiplatelet agents, has been utilized either as a standalone medication or in combination with aspirin for averting vascular complications in patients afflicted with atherothrombotic conditions. The selective and irreversible blockade of the P2Y12 receptor by clopidogrel makes it a potent inhibitor of platelet activation and aggregation. In patients with acute coronary syndromes or undergoing percutaneous interventions, combining clopidogrel with aspirin is a crucial approach to antiplatelet therapy. The aim of this review article is to investigate the factors that contribute to clopidogrel resistance, mechanisms involved in clopidogrel resistance, evaluate it through laboratory methods and clinical implications of clopidogrel resistance. Additionally, the article explores the clinical importance of Clopidogrel Resistance and its correlation with harmful cardiovascular events. The paper concludes by proposing potential solutions to this resistance and suggesting the usage of alternative antiplatelet from the new generation.
Keywords:
Clopidogrel Resistance; Platelet Aggregation; P2Y12 Receptor; Ticagrelor; “Gold Standard” Method
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0